Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corner Growth Acquisition Corp. - Class A Ordinary Shares (NQ:COOL)

11.10 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Corner Growth Acquisition Corp. - Class A Ordinary Shares

Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. 
Via Benzinga
How Bad Are PolarityTE's Earnings? | Return On Capital Employed
PolarityTE (NASDAQ:PTE) brought in sales totaling $2.54 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 5.1%, resulting in a loss of $8.... 
Via Benzinga
PolarityTE Stock Drops On FDA Clinical Hold On SkinTE Trial Application
The FDA has issued a clinical hold on PolarityTE Inc's (NASDAQ: PTE) SkinTE Investigational New Drug Application (IND) for chronic cutaneous ulcers. The... 
Via Benzinga
PTE Stock: The FDA News That Has Biotech Penny Stock PolarityTE Plunging Today
PolarityTE (PTE) stock is taking a beating on Tuesday after the biotechnology company got an update from the FDA on its IND. 
Via InvestorPlace
PolarityTE's SkinTE Meets Primary, Secondary Endpoint Goals In Diabetic Foot Ulcer Trial
PolarityTE Inc (NASDAQ: PTE) has announced final data from a trial evaluating SkinTE plus standard of care (SOC) vs. SOC alone for Diabetic Foot Ulcers. The trial... 
Via Benzinga
PolarityTE Stock Drops On Wider Than Expected Q1 Loss, SkinTE Transitions To BLA Pathway
PolarityTE Inc (NASDAQ: PTE) reported a Q1 EPS loss of $(0.24), missing the consensus of $(0.12) loss, but better than $(0.39) loss a year ago. Sales of $... 
Via Benzinga
Why PolarityTE Shares Are Trading Higher On Monday
PolarityTE (NASDAQ: PTE) shares are trading higher after the company announced its Diabetic Foot Ulcers trial met its primary and secondary endpoints. In the company's multi-... 
Via Benzinga
PolarityTE Stock Jumps As SkinTE Aces Diabetic Foot Ulcer Trial
PolarityTE Inc (NASDAQ: PTE) has announced preliminary topline data from a multi-center randomized controlled trial evaluating SkinTE for the... 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.